CH5183284 (Debio-1347) is primarily investigated for its potential in cancer treatment, particularly targeting tumors with specific genetic mutations. It acts as a selective inhibitor of FGFR (fibroblast growth factor receptor) kinases, which are often implicated in the growth and survival of certain cancers. By inhibiting these receptors, it aims to disrupt signaling pathways that promote tumor progression. This makes it a promising candidate for treating cancers such as bladder, lung, and breast cancer, where FGFR alterations are common. Clinical trials are ongoing to evaluate its efficacy and safety in patients with advanced solid tumors harboring FGFR genetic abnormalities.